For those interested, Acadia have just presented at the 39th J P Morgan healthcare conference. They confirmed that the Phase 3 trial for Retts remains on schedule for H2 2021. I would suggest that means the last patient to enroll is very close. This should be a market sensitive announcement as it is a significant milestone. I can provide countless other Boitechs who have announced same and been deemed market sensitive. IMU announced on 7th January.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$19.82 |
Change
-0.320(1.59%) |
Mkt cap ! $2.503B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.83 | $19.70 | $21.46M | 1.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7078 | $19.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.94 | 3500 | 1 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |